Dr. Roschewski on the Use of DA-EPOCH-R in Burkitt Lymphoma
Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.
Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.
A recent study by the NCI investigated DA-EPOCH-R in patients with Burkitt lymphoma. The primary endpoint was event-free survival (EFS), with secondary endpoints of progression-free survival, time to progression, overall survival and predictive ability of PET after 2 cycles. Results showed that this regimen is active and efficacious in adults of all ages with Burkitt lymphoma, with a favorable 3-year EFS compared to intensive regimens.
Roschewski says that DA-EPOCH-R is extremely effective in Burkitt lymphoma. Moving from a more intensive regimen to a less-intensive regimen can make some clinicians anxious, but Roschewski believes that the data support this approach. DA-EPOCH-R should be the standard approach for adult patients with Burkitt lymphoma, Roschewski concludes.
